xopenex การใช้

• The first approved usage for Xopenex will be for the relief and prevention of bronchial spasms.
• He forecast Xopenex sales of about $ 25 million in its first year, peaking at $ 150 million.
• In addition, a Sepracor product called Xopenex, which is an asthma drug, is doing incredibly well.
• Sepracor also sells a drug on its own, Xopenex, an asthma drug that had sales of $ 122 million last year.
• However, patients are expected to use just three doses of Xopenex a day, compared with four for the older drug, Traversa said.
• After going public in 1991, Sepracor brought a number of chiral and active-metabolite drugs to market, including Allegra, Xopenex, and Lunesta.
• On its own, Sepracor plans this winter to launch the US sale of an asthma drug, Xopenex, as a successor to two other medications that already have lost US patent protection.
• The generic name for Xopenex is levalbuterol, which the company says is an improved version of albuterol, the world's leading asthma treatment, which works by dilating the bronchial tubes.
• Another boost came in July, when the FDA said Sepracor had cleared the major hurdles of the review process for its second product, and its first without a partner _ the asthma inhalation solution Xopenex.
• Sepracor has indicated that it will price Xopenex comparably to Glaxo's Ventolin, which sells for about $ 1.75 a dose; the generics typically sell for $ 1.25 a dose.
• Sepracor Inc ., a biotechnology company based in Marlborough, Mass ., said Friday that it had received approval from the Food and Drug Administration to begin marketing a new inhalable drug named Xopenex for the treatment of asthma.
• Monday's strong quarterly results showed that royalties from Allegra, an allergy medication developed for Aventis S . A ., and Xopenex, Sepracor's own asthma drug, generated $ 27.1 million of the company's $ 33.9 million in total revenues for the period.
• EMT-IVs are trained to the NREMT-B standard in accordance with DOT regulations, as well as receive additional training in advanced airway management, administration of epinephrine 1 : 1000 in anaphylaxis, administration of nebulized and aerosolized Beta-2 agonists such as Xopenex and albuterol, administration of D50W and D25W, IV therapy and access, and trauma life support including the use of MAST trousers.